Sponsor study identifier
Secondary identifiers
interventional
90
1 country
1
Study Start
April 2010
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
February 2016
Actual (reported)Study Completion
February 2016
Actual (reported)The investigators are investigating whether a hormone that is naturally produced by the human body, called testosterone, can help improve weight, disordered eating, depression, and anxiety. The investigators hypothesize that testosterone will be a novel and effective endocrine-targeted therapy for patients with anorexia nervosa.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 2016
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 2010
Date type not reportedThis date has not been verified as actual or estimated.
May 10, 2010
Actual (reported)May 12, 2010
Actual (reported)February 2016
Actual (reported)February 2016
Actual (reported)April 26, 2017
Actual (reported)Change From Baseline in Weight
Weight in kilograms
Baseline, 24 Weeks
Change From Baseline in Depression Symptom Severity
Hamilton Depression Rating Scale (HAM-D) (Higher score = greater depression symptom severity; Score Range 0 - ≥ 23)
Baseline, 24 weeks
Testosterone x 24 weeks
Placebo x 24 weeks
Testosterone 300mcg transdermal patch x 24 weeks.
Placebo transdermal patch x 24 weeks
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Massachusetts General Hospital
Boston, Massachusetts, 02144, United States
Plessow F, Galbiati F, Eddy KT, Misra M, Miller KK, Klibanski A, Aulinas A, Lawson EA. Low oxytocin levels are broadly associated with more pronounced psychopathology in anorexia nervosa with primarily restricting but not binge/purge eating behavior. Front Endocrinol (Lausanne). 2023 Jan 31;13:1049541. doi: 10.3389/fendo.2022.1049541. eCollection 2022.
Kimball A, Schorr M, Meenaghan E, Bachmann KN, Eddy KT, Misra M, Lawson EA, Kreiger-Benson E, Herzog DB, Koman S, Keane RJ, Ebrahimi S, Schoenfeld D, Klibanski A, Miller KK. A Randomized Placebo-Controlled Trial of Low-Dose Testosterone Therapy in Women With Anorexia Nervosa. J Clin Endocrinol Metab. 2019 Oct 1;104(10):4347-4355. doi: 10.1210/jc.2019-00828.
Anne Klibanski, MD
Massachusetts General Hospital
Karen K Miller, MD
Massachusetts General Hospital
Erinne Meenaghan, NP
Massachusetts General Hospital
90 participants (actual enrollment reported by the registry).
First Submitted
May 10, 2010
First Posted
May 12, 2010
Study Start
April 2010
Date type not reportedThis date has not been verified as actual or estimated.
To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone
Contact the study team to confirm eligibility.
Primary Completion
February 2016
Actual (reported)Study Completion
February 2016
Actual (reported)Last Updated
September 2, 2020
Results First Posted
April 26, 2017
Record last verified: 2020-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: